Pfizer ( Pfizer )


Pfizer's picture

Good health is vital to all of us, and finding sustainable solutions to the most pressing health care challenges of our world cannot wait. That's why we at Pfizer are committed to applying science and our global resources to improve health and well-being at every stage of life. We strive to provide access to safe, effective and affordable medicines and related health care services to the people who need them.

We have a leading portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and we have an industry-leading pipeline of promising new products that have the potential to challenge some of the most feared diseases of our time, like Alzheimer's disease and cancer.

Pfizer press release, blog etc

07/16/2018 - 16:27 Pfizer Initiates Pivotal Phase 3 Program for Investigational Hemophilia B Gene Therapy
07/13/2018 - 15:22 U.S. FDA Approves XTANDI (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
07/11/2018 - 18:01 Pfizer to Organize for Future Growth
06/27/2018 - 21:08 XELJANZ (tofacitinib citrate) Receives Marketing Authorisation in the European Union for Active Psoriatic Arthritis
06/27/2018 - 01:30 U.S. FDA Grants Priority Review for Pfizers New Drug Application for Glasdegib in Patients with Previously Untreated Acute Myeloid Leukemia
06/25/2018 - 01:42 Pfizer Announces Overall Survival Results from Phase 3 PALOMA-3 Trial of IBRANCE (Palbociclib) in HR+, HER2- Metastatic Breast Cancer
06/11/2018 - 21:17 Pfizer Announces Extension of Zithromax Antibiotic Donation Program through 2025 to Help Eliminate Worlds Leading Infectious Cause of Blindness
06/07/2018 - 09:28 U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Talazoparib for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation
06/06/2018 - 09:32 Pfizer to Expand Venture Investing with $600 Million Commitment to Pfizer Ventures
06/03/2018 - 21:58 Dacomitinib Shows More than Seven-Month Improvement in Overall Survival Compared to an Established Therapy in Advanced NSCLC with EGFR-Activating Mutations
06/01/2018 - 08:57 Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, TRAZIMERA (trastuzumab)
05/30/2018 - 07:11 The Pfizer Foundation Announces $5 Million in Grants to Support Women and Families
05/23/2018 - 07:24 FDA Grants Breakthrough Therapy Designation for Tafamidis for the Treatment of Patients with Transthyretin Cardiomyopathy
05/22/2018 - 13:27 A Study Analyzing Observational Data Shows Real-World Effectiveness of Prevnar 13 in Adults Age 65+
05/22/2018 - 03:41 Pfizer Begins a Phase 1/2 Study to Evaluate Respiratory Syncytial Virus (RSV) Vaccine
05/17/2018 - 09:00 LYRICA (pregabalin) Oral Solution CV Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint
05/16/2018 - 15:18 Pfizer Oncology to Showcase Clinical Advances from its Growing Portfolio and Research Pipeline at ASCO
05/15/2018 - 10:04 Pfizers Biosimilar RETACRIT (epoetin alfa-epbx) Approved by U.S. FDA